The impact of the recent AAP changes in palivizumab authorization on RSV-induced bronchiolitis severity and incidence
Open Access
- 14 August 2017
- journal article
- letter
- Published by Springer Science and Business Media LLC in Italian Journal of Pediatrics
- Vol. 43 (1), 1-5
- https://doi.org/10.1186/s13052-017-0390-8
Abstract
Following the most recent modification by the American Academy of Pediatrics, based on American studies on RSV epidemiology, the Italian Drug Agency (AIFA) decided to limit the total financial coverage of the palivizumab prescription by the National Health Service only to the < 29 wGA group and age ≤ 12 months at the beginning of the RSV epidemic season. However, the vulnerability of otherwise healthy premature infants ≥ 29 wGA has been demonstrated in Italian analyses. We retrospectively reviewed records from children ≤ 1 years of age admitted for RSV-induced ALRI at the Gaslini Hospital, over three consecutive RSV epidemic seasons (RES) (2014–2017). We found that the prescription limitation on RSV immunoprophylaxis in preterms was associated in the 2016–2017 RES with: a) a high proportion of admission for the < 36 wGA infants, the great majority born at 33- < 36 wGA and a chronological age of < 6 months; b) a high proportion of preterms treated with high flow nasal cannula ventilation. These results strongly point to a need to reevaluate the role of palivizumab prophylaxis in the >= 29 wGA subpopulation when specific risk factors are present.Keywords
Funding Information
- Ministero della Salute (Ricerca corrente 2016)
This publication has 8 references indexed in Scilit:
- Indications to respiratory syncytial virus immunoprophylaxis in the 29–32 wGA group: is there still room for debating?Italian Journal of Pediatrics, 2017
- Respiratory Syncytial Virus-associated hospitalization in premature infants who did not receive palivizumab prophylaxis in Italy: a retrospective analysis from the Osservatorio StudyItalian Journal of Pediatrics, 2016
- Revised recommendations concerning palivizumab prophylaxis for respiratory syncytial virus (RSV)Italian Journal of Pediatrics, 2015
- Inter-society consensus document on treatment and prevention of bronchiolitis in newborns and infantsItalian Journal of Pediatrics, 2014
- Updated Guidance for Palivizumab Prophylaxis Among Infants and Young Children at Increased Risk of Hospitalization for Respiratory Syncytial Virus InfectionPEDIATRICS, 2014
- Respiratory Syncytial Virus–Associated Hospitalizations Among Children Less Than 24 Months of AgePEDIATRICS, 2013
- The Burden of Respiratory Syncytial Virus Infection in Young ChildrenThe New England Journal of Medicine, 2009
- Respiratory syncytial virus and premature infants born at 32 weeks' gestation or earlier: hospitalization and economic implications of prophylaxis.2000